Metaphysica: The virtual reality escape room everyone should try – The RiotACT

Shannon Pickles says gamers love the virtual reality experience at Metaphysica in Mitchell. Photo: Sharon Kelley.

Lighting Rock is a software development studio using virtual reality to provide all kinds of experiences to people in Canberra, from helping physics students visualise and manipulate magnetic and electronic fields, to creating virtual environments in which students can pour a concrete slab and see the consequences of not pouring the correct way.

The studios Metaphysica virtual reality gaming space at 30 Kemble Court in Mitchell is another project its engineers have worked on and it is taking Canberra by storm.

Metaphysica is a virtual reality escape room, where contestants enter an empty padded room, don virtual reality headsets and are fully immersed inside the game experience.

Gamers love it, but its good for everyone, says Lighting Rocks Shannon Pickles. We dont have anything scary; its suitable for all ages and you get to experience an entire virtual world, whether or not you want to do the puzzles and solve the escape room.

The experience of virtual reality can amaze people and they never get around to solving puzzles. They just wander around for the experience of it, particularly people who havent tried it before.

But other people go in as a team and solve the puzzles. The good thing is we dont have to rebuild the room physically to change the puzzles we just change the software.

Huxley: Save the Future is one of the virtual reality escape room experiences at Metaphysica. Image: Supplied.

Lightning Rock is currently using software from a European partner Huxley and Huxley 2 but is moving to make the virtual escape rooms its own, and is currently designing its own software to change the experience.

Customers can play either game, and once entered into the specially designed physical room, surround sound and virtual reality headsets transport them to a fictional world, which is graphically beautiful and has many aspects to explore.

Its great, says Shannon, We can sit at the desk and play with the software, meaning only one person will see a crucial element while others wont. We can play with physics, challenge perceptions, we can make the virtual world do anything. It has so many applications.

The Metaphysica experience is also COVID-19 safe, says Shannon. Headsets and controllers are meticulously cleaned with ultraviolet light sanitisers before and after each use, and the company has placed its COVID-19 policy and practice prominently on the Metaphysica website. Customers will not need to touch anything but the sanitised headsets and controllers.

Playing Huxley is an experience youll never forget. Image: Supplied.

The headsets are light and theres no need for microphones because you are speaking to your own team inside the same room. There are no backpacks, just the headset and a game controller. Surround sound inside the game room completes the virtual world. Each room is air-conditioned to keep temperatures comfortable.

Metaphysica is open from 10 am to 11 pm, with the average customer taking around 45 minutes to an hour to complete the game.

Groups are limited to three people per room. Customers should be above the age of 10, and at least 110cm tall. Two groups of three can play simultaneously in a team challenge, and Metaphysica is currently developing new technology that will allow groups of up to four people per room eight for team challenges within the next few weeks.

You can make an online booking at Metaphysica, or call Shannon on 0414 944 934. Gift certificates are also available from the Metaphysica website.

Read more:

Metaphysica: The virtual reality escape room everyone should try - The RiotACT

Augmented Reality and Virtual Reality Lens Market Outlook and Opportunities in Grooming Regions – Market Research Posts

The report Global Augmented Reality and Virtual Reality Lens Market intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Also identifies and analyses the emerging trends along with major drivers, challenges, opportunities and entry strategies for various companies in the Global Augmented Reality and Virtual Reality Lens Industry.Global Augmented Reality and Virtual Reality Lens Market Research report provides information regarding market size, share, trends, growth, cost structure, capacity, revenue and forecast 2024. This report also includes the overall and comprehensive study of the Augmented Reality and Virtual Reality Lens market with all its aspects influencing the growth of the market. This report is exhaustive quantitative analyses of the Augmented Reality and Virtual Reality Lens industry and provides data for making strategies to increase the market growth and effectiveness.

The Global Augmented Reality and Virtual Reality Lens market research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Global Augmented Reality and Virtual Reality Lens Market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

Request Free Sample Pages Of This Premium Research Report: https://www.researchmoz.us/enquiry.php?type=S&repid=2730944

The authors of the report have segmented the global Augmented Reality and Virtual Reality Lens market as per product, application, and region. Segments of the global Augmented Reality and Virtual Reality Lens market are analyzed on the basis of market share, production, consumption, revenue, CAGR, market size, and more factors. The analysts have profiled leading players of the global Augmented Reality and Virtual Reality Lens market, keeping in view their recent developments, market share, sales, revenue, areas covered, product portfolios, and other aspects.The Augmented Reality and Virtual Reality Lens market report helps the readers grasp the changing trend in the industry supply chain, manufacturing techniques and expenses, and current scenario of the end uses in the global Augmented Reality and Virtual Reality Lens market.

All the players running in the global Augmented Reality and Virtual Reality Lens market are elaborated thoroughly in the Augmented Reality and Virtual Reality Lens market report on the basis of proprietary technologies, distribution channels, industrial penetration, manufacturing processes, and revenue. In addition, the report examines R&D developments, legal policies, and strategies defining the competitiveness of the Augmented Reality and Virtual Reality Lens market players.

This report covers leading companies associated in Augmented Reality and Virtual Reality Lens market:

Scope of Augmented Reality and Virtual Reality Lens Market:The global Augmented Reality and Virtual Reality Lens market is valued at million US$ in 2017 and will reach million US$ by the end of 2025, growing at a CAGR of during 2018-2025.

This Market Report includesdrivers and restraints of the global Augmented Reality and Virtual Reality Lens market and their impact on each region during the forecast period. The report also comprises the study of current issues with consumers and opportunities. It also includes value chain analysis.

On the basis Of the end users/applications,this report focuses on the status and outlook for major applications/end users, sales volume, Augmented Reality and Virtual Reality Lens market share and growth rate of Augmented Reality and Virtual Reality Lens foreach application, including-

On the basis of product,this report displays the sales volume, revenue (Million USD), product price, Augmented Reality and Virtual Reality Lens market share and growth rate ofeach type, primarily split into-

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @ https://www.researchmoz.us/enquiry.php?type=E&repid=2730944

Augmented Reality and Virtual Reality Lens Market: Regional analysis includes:

Augmented Reality and Virtual Reality Lens Market Report Structure at a Glance:

For More Information Kindly Contact: ResearchMozMr. Rohit Bhisey,90 State Street,Albany NY,United States 12207Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email: [emailprotected]Follow us on LinkedIn @ http://bit.ly/1TBmnVGMedia Release: https://www.researchmoz.us/pressreleaseFollow me on : http://marketresearchlatestreports.blogspot.com/

Read more:

Augmented Reality and Virtual Reality Lens Market Outlook and Opportunities in Grooming Regions - Market Research Posts

The Limitations and Promise of Genetic Testing in Psychiatry – Psych Congress Network

Genetic testing may be a helpful tool in diagnosing autism and intellectual disability, but published data does not adequately support its use as a standard predictor of antidepressant response, James B. Potash, MD, MPH, said during a session at the virtual 2020 Psych Congress Elevateconference on the role of genetic testing in psychiatry.

There is ample reason to think that genetic variation ought to predict antidepressant response but research has shown mixed results, said Dr. Potash, who is the Henry Phipps Professor, Director and Psychiatrist-in-Chief, at Johns Hopkins Medicine, Baltimore, Maryland, and has been working in the field of genetics of mood disorders for more than 20 years.

Dr. Potash is a member of the American Psychiatric Association Council on Research, which had a task force analyze the issue in recent years. In a systematic review of pharmacogenetic tests of antidepressants, the task force found that the quality of the data provided by the tests on pharmacodynamicshow a drug affects the brainwas low, he said. However, the study, published in The American Journal of Psychiatry, found the tests provided higher-quality data on regarding particular genes related to how a drug is metabolized in the liver.

Their conclusion was at present there are insufficient data to support the widespread use of combinatorial pharmacogenetic testing in clinical practice, although there are clinical situations in which the technology may be informative, particularly in predicting side effects, Dr. Potash explained.

Similarly, an International Society of Psychiatric Genetics committee on genetic testing last year reached the conclusion that evidence to support widespread use of pharmacogenetic tests is inconclusive. But the statement also says when pharmacogenetic testing results are already available, providers are encouraged to integrate this information into their medication selection and dosing decisions, he said.

As for the future direction of genetic testing in psychiatry, Dr. Potash said there is ongoing research into its use in bipolar disorder.

A study involving 2500 people with bipolar disorder, published in Lancet by the International Consortium on Lithium Genetics, found some genetic variations were statistically significantly associated with response to lithium treatment. People with the highest Polygenic Risk Score (PRS) for schizophrenia had the lowest response to lithium treatment, and people with the lowest schizophrenia PRS had the highest response to lithium treatment. In addition, a paper recently published in Molecular Psychiatry found that people with bipolar disorder who had the lowest PRS for depression were 75% more likely to respond favorably to lithium, compared with those with the highest depression PRS scores.

Dr. Potash also spoke about the importance of a more traditional genetic research tool: collecting a detailed family history from a patient.

It has been known for a long time but its not always implemented, he said, noting that familial recurrence risk has been analyzed for more than 100 years.

For example, he explained, if one parent has schizophrenia and no siblings or second-degree relatives do, a child has a 6% risk of developing schizophrenia. But if one parent, two siblings, and a second-degree have the disorder, the relative the risk of a child inheriting it is 36%.

That kind of information is important, he said. Very important. Its valuable.

Terri Airov

References

Amare AT, Schubert KO, Hou L.,et al.Association of polygenic score for major depression with response to lithium in patients with bipolar disorder.Molecular Psychiatry. 2020 March 16;[Epub ahead of print].

Genetic Testing Statement. International Society of Psychiatric Genetics. Accessed July 15, 2020.

Hou L, Heilbronner U, Degenhardt F, et al. Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet. 2016;387(10023):1085-1093.

The role of genetic testing in psychiatry. Presented at Psych Congress Elevate: Virtual; July 26, 2020.

Zeier Z, Carpenter LL, Kalin NH, et al. Clinical implementation of pharmacogenetic decision support tools for antidepressant drug prescribing. The American Journal of Psychiatry. 2018;175:873886.

View original post here:

The Limitations and Promise of Genetic Testing in Psychiatry - Psych Congress Network

Choosing the Best Pancreatic Cancer Doctor and Hospital for You – Pancreatic Cancer News & Stories

When someone is diagnosed with cancer especially a particularly difficult kind like pancreatic cancer they often look for the best.

The best treatment. The best doctor. The best hospital. The best chance.

When it comes to pancreatic cancer, the best healthcare team is:

And if you are considering or getting surgery, the Pancreatic Cancer Action Network (PanCAN) recommends seeing a surgeon who performs more than 15 pancreatic surgeries per year to determine your eligibility and to perform the surgery.

If you have a rare form of pancreatic cancer (any type other than pancreatic adenocarcinoma), it is also important to see a doctor who has experience treating your specific type of cancer, if possible.

When trying to find the best doctors and center for you, it is important to consider finances and insurance coverage, whether you are able to travel, what type of pancreatic cancer you have, what your treatment goals are and what you are looking for in a healthcare team.

PanCAN keeps a list of pancreatic cancer specialists and high-volume centers throughout the country. Contact our Patient Services for specialists that meet your needs, such as expertise and geography.

Pancreatic cancer is relatively rare, and its treatment requires specialized knowledge and experience. While local hospitals can offer quality care, large academic cancer centers may be more likely to have doctors who are up to date on pancreatic cancer treatments and research.

These centers are also more likely to offer more clinical trials, a multidisciplinary team and support services than smaller, local hospitals.

Its important to remember that every patient is different, has different needs and responds to treatment differently.

Precision medicine treatment based on a persons or their tumors biology may help find the treatment that is best for you. PanCANs Know Your Tumor precision medicine service can help eligible patients access tumor biomarker testing and genetic testing to tell you about your biology and inform treatment decisions, regardless of where you are being treated. Contact PanCANs Patient Services for more information about precision medicine and Know Your Tumor.

When considering a doctor, ask:

Remember that your healthcare team is made up of more than just your doctor, and all roles are critical. For example, PanCAN recommends patients see a registered dietitian who has experience working with cancer patients. This person may be a part of your doctors or institutions care team, or they may be found outside of it.

No matter what, be sure to ask any current or prospective healthcare team members questions. Its important that you feel comfortable and supported by your healthcare team.

During the coronavirus pandemic, you may have additional challenges finding a doctor. Hospitals and institutions all have different policies right now. If the doctor or institution you are working with or want to see is not providing what you need, contact Patient Services. Our team can help you figure out other options, including helping you find another specialist or treatment center if needed.

And right now, advocating for yourself is more critical than ever. PanCAN is always here to support you in that endeavor and with anything else you may need.

Follow this link:

Choosing the Best Pancreatic Cancer Doctor and Hospital for You - Pancreatic Cancer News & Stories

jCyte Inc. Announces Promising Phase 2b Results of jCell Therapy in Retinitis Pigmentosa – Business Wire

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--jCyte Inc., a biotech company dedicated to preserving and restoring vision in patients with retinitis pigmentosa and other degenerative retinal disorders, announced today promising results from a Phase 2b clinical trial of jCell in retinitis pigmentosa (RP), an inherited retinal disease, irrespective of genetic subtype.

jCell is a first-in-class investigational treatment for RP which has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation. In addition to RMAT, jCell has received Orphan Drug designation from the FDA and the European Medicines Agency (EMA).

The Phase 2b trial was a multicenter, randomized study that evaluated the safety and efficacy of intravitreal injection of jCell therapy in adult subjects with RP. A large and broad set of patients with RP with best-corrected visual acuity (BCVA) between 20/80 and 20/800 were randomized to treatment versus sham. Treatment consisted of a single intravitreal injection of either 3 or 6 million human retinal progenitor cells (hRPC). The study evaluated changes in visual function and functional vision in subjects with RP who received a single jCell injection in comparison to a sham-treated control group.

The primary endpoint in the Phase 2b study was mean change in best corrected visual acuity (BCVA) from baseline to month 12. Secondary endpoints included low light mobility, contrast sensitivity, kinetic visual fields, and a visual function questionnaire. In a post hoc exploratory analysis, the primary and secondary endpoints were assessed in a target subgroup of patients meeting the following criteria: 1) study eye with reliable fixation (12 central diameter and/or steady central fixation) and 2) study eye did not have significantly worse BCVA than the fellow eye (15 letters).

The Phase 2b clinical trial was specifically designed to learn more about the clinical effects of jCell therapy in a broad set of patients suffering from RP to better understand three critical study variables: the optimal jCell dose, the performance of clinical trial endpoints in the study population and the RP patient population likely to realize the most pronounced improvement from a single jCell treatment during the 12-month pivotal trial study period.

Phase 2b Results

A total of 84 patients were randomized of which 74 met criteria for the per protocol analysis. The mean change in BCVA from baseline to month 12 were +2.81, +2.96, and +7.43 letters in the sham (N=26), 3.0x106 hRPC (N=25), and 6.0x106 hRPC (N=23) treatment arms, respectively. In a post hoc exploratory analysis of the target subgroup (n=37), mean change in BCVA from baseline to month 12 were +1.85, -0.15, and +16.27 letters in the sham (N=13), 3.0x106 hRPC (N=13), and 6.0x106 hRPC (N=11) treatment arms, respectively (p=0.003 for 6.0x106 hRPC vs sham). Supportive improvements in the 6.0x106 hRPC target subgroup compared to the control (sham) group were also observed in all secondary endpoints which further support the BCVA findings in this subpopulation. Adverse events were generally minor and transient; there was one serious adverse event in the 3.0x106 hRPC arm of Grade 3 ocular hypertension that resolved with treatment, but no serious adverse events nor any adverse events greater than Grade 1 (mild) in the higher, 6 million cell treatment group during the 12-month study period that were related to the study treatment.

Based on these results, the company plans to advance jCell into a pivotal trial utilizing the data generated, which is supportive of both the efficacy and safety of jCell therapy in a broad set of RP patients. The Phase 2b study also provides essential insights into the three critical study variables which are key to optimizing the probability of technical success of the upcoming jCell pivotal trial.

There is currently no effective treatment for RP, and once photoreceptors are lost, they do not regenerate. The promising results from this Phase 2b study suggest that jCell therapy in patients with RP can result in significant slowing of visual deterioration and an improvement in function of existing photoreceptors. The primary goal of jCell therapy is to preserve, and potentially improve vision by intervening in the disease process at a time when dystrophic photoreceptors can be protected and reactivated. We are excited to be continuing the development of jCell investigational therapy, based on these promising Phase 2b results, for patients with this degenerative retinal disease, said Anthony Joseph, M.D., Ophthalmic Consultants of Boston, who presented the Phase 2b data at the ASRS meeting.

We are thrilled to report these encouraging Phase 2b results from one of the largest studies ever conducted in RP, which indicate significant clinical activity of jCell in patients agnostic of genetic subtype, said Paul Bresge, Chief Executive Officer, jCyte, Inc. The Phase 2b results reported that jCell therapy had promising efficacy and was well tolerated in patients, and we plan to advance jCell into a pivotal clinical trial in 2021. There is currently no FDA approved treatment option for RP patients, irrespective of genetic subtype. We believe jCell has the potential to be the first approved therapy to address this critical unmet medical need, and dramatically improve the lives of patients with this progressive, blinding disease which typically presents early in the lives of the approximately 1:3500 people who are affected.

About Retinitis Pigmentosa (RP)

Retinitis pigmentosa (RP) is a rare, genetic condition that progressively destroys the rod and cone photoreceptors in the retina. It often strikes people in their teens, with many patients rendered legally blind by middle age. Worldwide, an estimated 1.9 million people suffer from the disease, including approximately 100,000 people in the U.S., making it the leading cause of inheritable blindness.

About jCyte, Inc.

jCyte, Inc. is a clinical-stage biotech company focused on developing jCell therapy for retinitis pigmentosa (RP) and other degenerative retinal disorders. jCell is a first-in-class investigational treatment for retinitis pigmentosa, an inherited retinal disease. The treatment is minimally-invasive and given as an intravitreal injection. There are currently no FDA approved therapies for RP agnostic of genetic subtype. The company is pioneering a new era of regenerative therapies to treat patients with unmet medical needs. For more information, visit http://www.jcyte.com

Read more:

jCyte Inc. Announces Promising Phase 2b Results of jCell Therapy in Retinitis Pigmentosa - Business Wire

New study reveals how day- and night-biting mosquitoes respond differently to colors of light and time of day – Newswise

Newswise Irvine, CA July 27, 2020 In a new study, researchers found that night- versus day-biting species of mosquitoes are behaviorally attracted and repelled by different colors of light at different times of day. Mosquitoes are among major disease vectors impacting humans and animals around the world and the findings have important implications for using light to control them.

The University of California, Irvine School of Medicine-led team studied mosquito species that bite in the daytime (Aedes aegypti, aka the Yellow Fever mosquito) and those that bite at night (Anopheles coluzzi, a member of the Anopheles gambiae family, the major vector for malaria). They found distinct responses to ultraviolet light and other colors of light between the two species. Researchers also found light preference is dependent on the mosquitos sex and species, the time of day and the color of the light.

Conventional wisdom has been that insects are non-specifically attracted to ultraviolet light, hence the widespread use of ultraviolet light bug zappers for insect control. We find that day-biting mosquitoes are attracted to a wide range of light spectra during the daytime, whereas night-biting mosquitoes are strongly photophobic to short-wavelength light during the daytime, said principal investigator Todd C. Holmes, PhD, a professor in the Department of Physiology and Biophysics at the UCI School of Medicine. Our results show that timing and light spectra are critical for species-specific light control of harmful mosquitoes.

The new study titled, Circadian Regulation of Light-Evoked Attraction and Avoidance Behaviors in Daytime- versus Nighttime-Biting Mosquitoes, is published in Current Biology. Lisa S. Baik, a UCI School of Medicine graduate student researcher who recently completed her PhD work, is first author.

Mosquitoes pose widespread threats to humans and other animals as disease vectors. It is estimated historically that diseases spread by mosquitoes have contributed to the deaths of half of all humans ever to have lived. The new work shows that day-biting mosquitoes, particularly females that require blood meals for their fertilized eggs, are attracted to light during the day regardless of spectra. In contrast, night-biting mosquitoes specifically avoid ultraviolet (UV) and blue light during the day. Previous work in the Holmes lab using fruit flies (which are related to mosquitoes) has determined the light sensors and circadian molecular mechanisms for light mediated attraction/avoidance behaviors. Accordingly, molecular disruption of the circadian clock severely interferes with light-evoked attraction and avoidance behaviors in mosquitoes. At present, light-based insect controls do not take into consideration the day versus night behavioral profiles that change with daily light and dark cycles.

Light is the primary regulator of circadian rhythms and evokes a wide range of time-of-day specific behaviors, said Holmes. By gaining an understanding of how insects respond to short wavelength light in a species-specific manner, we can develop new, environmentally friendly alternatives to controlling harmful insects more effectively and reduce the need for environmentally damaging toxic pesticides.

This study was funded in part by the National Institutes of Health, National Science Foundation and the ARCS Foundation. This new research builds on the Holmes labs previous studies at the UCI School of Medicine published over the past few years in Science, Nature and Proceedings of the National Academy of Sciences.

About the UCI School of Medicine

Each year, the UCI School of Medicine educates more than 400 medical students, and nearly 150 doctoral and masters students. More than 700 residents and fellows are trained at UCI Medical Center and affiliated institutions. The School of Medicine offers an MD; a dual MD/PhD medical scientist training program; and PhDs and masters degrees in anatomy and neurobiology, biomedical sciences, genetic counseling, epidemiology, environmental health sciences, pathology, pharmacology, physiology and biophysics, and translational sciences. Medical students also may pursue an MD/MBA, an MD/masters in public health, or an MD/masters degree through one of three mission-based programs: the Health Education to Advance Leaders in Integrative Medicine (HEAL-IM), the Leadership Education to Advance Diversity-African, Black and Caribbean (LEAD-ABC), and the Program in Medical Education for the Latino Community (PRIME-LC). The UCI School of Medicine is accredited by the Liaison Committee on Medical Accreditation and ranks among the top 50 nationwide for research. For more information, visit som.uci.edu.

###

More here:

New study reveals how day- and night-biting mosquitoes respond differently to colors of light and time of day - Newswise

Encoded Therapeutics Announces $135 Million Series D Financing to Support First Clinical Trials in SCN1A+ Dravet Syndrome and Advance Preclinical…

SOUTH SAN FRANCISCO, Calif., July 22, 2020 /PRNewswire/ --Encoded Therapeutics, Inc.(Encoded), a precision gene therapy company, today announced it has raised $135 million in an oversubscribed Series D financing. The company also announced that its lead asset, ETX101, was granted Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation by the U.S. Food and Drug Administration (FDA) for the treatment of SCN1A+ Dravet Syndrome.

GV (formerly Google Ventures) led the Series D financing with participation from Matrix Capital Management, ARCH Venture Partners, Illumina Ventures, RTW Investments, Boxer Capital, Nolan Capital, HBM Genomics, Menlo Ventures, Meritech Capital, Farallon Capital Management, SoftBank Vision Fund 21, and additional unnamed investors.

"I am incredibly proud of the progress our organization has made over the past year. We have built an outstanding team, further advanced ETX101 towards the clinic, applied our technology to a series of pipeline programs, and expanded our capabilities to become a fully integrated organization. We are grateful to our investors for supporting our vision to transform patients' lives with cell type-selective genetic medicines," said Encoded co-founder and chief executive officer, Kartik Ramamoorthi, Ph.D.

"Since 2019, our company has attracted some of gene therapy's most experienced executive leaders to prepare ETX101 for the clinic and beyond. This well-rounded team has made significant advances in manufacturing, clinical development, and regulatory affairs for ETX101. By coupling these with an innovative discovery engine, Encoded is advancing its preclinical pipeline of gene therapies to patients suffering from devastating pediatric CNS diseases," said Encoded's board chairman, Sean Nolan.

Encoded's discovery engine combines biological and computational approaches to identify and screen human DNA sequences known as regulatory elements at a high throughput scale. The resulting multi-dimensional, large scale datasets are leveraged to design optimal gene therapy expression cassettes which more precisely control transgene expression. By recapitulating natural patterns of gene expression, the resulting gene therapy vectors can provide maximal therapeutic benefit, minimize off-target expression, and address genetic disorders that have previously been considered untreatable.

David Schenkein, M.D., general partner and co-leader of GV's life sciences team, will join the Encoded Board of Directors as an observer. "Encoded's cutting edge platform has the potential to impact a broad range of diseases across different organ systems. Importantly, Encoded has translated this innovation into a one-time, first-in-class precision gene therapy candidate for the treatment of SCN1A+ Dravet Syndrome, a devastating pediatric disease with significant unmet medical need. I am enthusiastic to work with this top-tier team in their mission to treat these underserved patients and advance a portfolio of innovative medicines," said Dr. Schenkein.

The company also announced that ETX101 was granted Orphan Disease and Rare Pediatric Disease Designation by FDA. Both programs offer incentives for the development of therapeutics for underserved populations.

Proceeds from the Series D will be used to conduct clinical trial activities including a natural history study to better understand the progression of SCN1A+ Dravet Syndrome as well as first-in-human trials for ETX101. Additionally, the funds will support progression of the company's pipeline of gene therapies being evaluated for additional pediatric CNS disorders.

About EncodedEncoded Therapeutics, Inc., is a biotechnology company developing precision gene therapies for a broad range of severe genetic disorders. Seeded by Venrock, ARCH Venture Partners, Illumina Ventures, andMatrix Capital Mangament, ourmission is to realize the potential of genomics-driven precision medicine by overcoming key limitations of viral gene therapy. We focus on delivering life-changing advances that move away from disease management and towards lasting disease modification. We are advancing our lead asset, ETX101, for the treatment of SCN1A+ Dravet Syndrome. For more information, please visitwww.Encoded.com.

About Dravet SyndromeDravet syndrome is a rare, severe genetic disorder that occurs in approximately 1 in 16,000 births worldwide. The disorder is characterized by uncontrolled seizures, ataxia, significant developmental delays, and an increased risk of early mortality due to sudden unexpected death in epilepsy (SUDEP). The majority of Dravet Syndrome cases are caused by loss-of-function mutations in the SCN1A gene. Current treatments reduce seizures but do not address the underlying cause of the disorderSCN1A haploinsufficiency. More information about Dravet Syndrome can be found at http://www.dravetfoundation.org.

Media Contacts

Sarah SuttonGlover Park Group[emailprotected]202-337-0808

Danielle CanteyGlover Park Group[emailprotected] 202-337-0808

_________________________________

1

As of the date of this press release, SoftBank Group Corp. has made capital contributions to allow investments by SoftBank Vision Fund 2 ("SVF 2") in certain portfolio companies. The information included herein is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy limited partnership interests in any fund, including SVF 2. SVF 2 has yet to have an external close, and any potential third-party investors shall receive additional information related to any SVF 2 investments prior to closing.

SOURCE Encoded Therapeutics, Inc.

Home

Read more here:

Encoded Therapeutics Announces $135 Million Series D Financing to Support First Clinical Trials in SCN1A+ Dravet Syndrome and Advance Preclinical...

The Government Should Stop Mandating the Use of "Race" in Medical and Scientific Studies – Reason

I was asked to contribute to a symposium on race, racism, and administrative law at Notice and Comment, the blog of the Yale Journal of Regulation. Given my current research on the American law of race, some of which I have blogged here, I had a lot to choose from; the most egregious forms of racial classification in the U.S. are largely the product of administrative decisions, rather than legislation. I ultimately decided to write about how the FDA and NIH require the use of ridiculously unscientific "racial" categories, adopted by the OMB for entirely different purposes in 1977, in biomedical research, and why this use of "race" should be abolished. Here's a taste, but you can read the whole thing at this link:

As of this writing, the federal government is considering using race and ethnicity to allocate access to a new Coronavirus vaccine to combat Covid-19 when one becomes available. More specifically, the government is considering giving preference to African Americans and Latinos because they have been disproportionately affected by the pandemic.

There are obvious dangers to allocating medical resources by race especially in a politically sensitive an area such as vaccines, where the public is already all-too-prone to accept various conspiracy theories and quackery that leads them to oppose vaccination. Instead of expanding the use of race in this way, science and medicine should be moving away from considering race and ethnicity at all.

Unfortunately, the FDA and NIH have mandated the use of race and ethnicity since the late 1990s. As a result of this mandate, the use of race has become so common in the scientific and medical communities that most people in the field fail to consider whether there is any justification for doing so. As one scientist reports, "we don't tend to think a lot about that [race] variable, what it means, how it's defined, how it's being used. We just sort of use it blindly."

This is very unfortunate, because, in addition to other problems discussed below, the FDA and NIH mandated that the "race variable' be based on the arbitrary (but now standard in American life) racial and ethnic classifications established by the Office of Management and Budget in 1977 for civil rights enforcement purposes. At the time, the OMB warned that the "classifications should not be interpreted as being scientific or anthropological in nature." This did not stop the FDA and NIH from institutionalizing them into medical and scientific research.

Any discussion of race in science and medicine must start with the recognition that variations in DNA that may have scientific or medical implications are not specific to race, as such, but to geographical distance between different populations. Additionally, there is no known example of polymorphism that is found exclusively in any particular "racial" group.

Even if at one time race may have been useful as a crude proxy for genetic heterogeneity, as DNA testing has become more available and much less expensive, race is a poor substitute for looking at actual discernible genetic differences between people. "Pooling people in race silos," an editorial in Nature Biotechnology declared, "is akin to zoologists grouping racoons, tigers, and okapis on the basis that they are all stripey."

The OMB category of Asian, meanwhile, is absurdly non-specific and unscientific. It includes people with origins everywhere from the Philippines to the Indian subcontinent. There are vast differences among the various ethnic groups that comprise the two billion or so people who live within the Indian subcontinent, much less between South Asians and East Asians.

Hispanic/Latino is an even more problematic category. Latinos' origins can be any combination of African, Asian, European, and Indigenous. Nor are they culturally homogenous. There is no reason to believe that data about Dominican residents of New York City is applicable to indigenous Mexican farm workers in California.

[S]upport for the idea that we should allow the government to use research based on arbitrary, scientifically ridiculous OMB racial categories to allocate medical resources to people based on those categories seems both fantastical and an unjustified triumph of unscientific racialist thinking. Unfortunately, this is what NIH's and FDA's imposition of the OMB categories into scientific research has wrought.

Original post:

The Government Should Stop Mandating the Use of "Race" in Medical and Scientific Studies - Reason

Merus announces FDA Orphan Drug Designation of Zenocutuzumab for the Treatment of Pancreatic Cancer – BioSpace

UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics) for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Zenocutuzumab (Zeno) for the treatment of patients with pancreatic cancer.

Zeno is a first in class bispecific antibody that potently binds to the HER2 and HER3 receptors, to potently block the interaction of HER3 with its ligand, neuregulin 1 (NRG1). Zeno has demonstrated promising early clinical responses in patients with previously treated pancreatic cancer harboring NRG1 gene fusions, as presented at the AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics in October 2019. The NRG1 gene fusion is a rare, powerful driver of cancer cell growth found in pancreatic, lung and other types of solid tumors. Zeno is now being evaluated in a global phase 1/2 clinical trial called the eNRGy trial.

Receiving Orphan Drug Designation for Zeno is another important milestone for our lead program, and it validates the significant unmet need in patients with pancreatic cancer, said Bill Lundberg, M.D., President, Chief Executive Officer and Principal Financial Officer of Merus. We are pleased with the progress we are making in our ongoing global clinical trial, and believe that Zeno has the potential to play a significant role in shifting the treatment paradigm for NRG1 fusion cancers from conventional chemotherapy to a personalized medicine approach.

The FDA grants Orphan Drug Designation to drugs that are intended to treat rare diseases that affect fewer than 200,000 people in the U.S. Orphan Drug Designation may provide Merus certain benefits, such as grant funding towards clinical trial costs, tax advantages and eligibility for seven-year market exclusivity.

Pancreatic cancer is estimated to occur in approximately 57,000 patients annually in the United States, according to the NCI SEER database. Pancreatic ductal adenocarcinoma (PDAC), the most common subtype of pancreatic cancer, is one of the most aggressive solid tumor cancers and the fourth leading cause of cancer related deaths.

About the eNRGy Clinical Trial Merus is currently enrolling patients on the Phase 1/2 eNRGy trial to assess the safety and anti-tumor activity of Zeno monotherapy in NRG1+ cancers. The eNRGy trial consists of three cohorts: NRG1+ pancreatic cancer; NRG1+ non-small cell lung cancer; and NRG1+ other solid tumors. Further details, including current trial sites, can be found at http://www.ClinicalTrials.gov and Merus trial website at http://www.nrg1.com or by calling 1-833-NRG-1234.

About NRG1 FusionsThe NRG1 gene encodes for neuregulin 1 (also known as heregulin), the ligand for HER3.Fusions between NRG1 and partner genes are rare genetic events occurring in patients with certain lung, pancreatic and other solid tumors, associated with activation of HER2/HER3 signaling and growth of cancer cells. NRG1 fusions are estimated to occur at a rate of approximately 0.5% - 1.5% in PDAC, based on the limited available published data.

About ZenoZeno is an antibody-dependent cell-mediated cytotoxicity (ADCC)-enhanced Biclonics that utilizes the Merus Dock & Block mechanism to inhibit the neuregulin/HER3 tumor-signaling pathway in solid tumors. Through its unique mechanism of binding to HER2 and potently blocking the interaction of HER3 with its ligand NRG1 or NRG1-fusion proteins, Zeno has the potential to be particularly effective against NRG1+ cancers. In preclinical studies, Zeno also potently inhibits HER2/HER3 heterodimer formation and tumor growth in models harboring NRG1 fusions.

Learn more aboutZeno Dock& Block athttps://merus.nl/technology/.

About MerusMerus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics. Multiclonics are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus website,www.merus.nlandhttps://twitter.com/MerusNV.

Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, the potential of Zeno to play a significant role in shifting the treatment paradigm for NRG1 fusion cancers from conventional chemotherapy to a personalized medicine approach; the progress of the eNRGy trial; and the potential benefits of the orphan drug designation of Zeno , such as grant funding towards clinical trial costs, tax advantages and eligibility for seven-year market exclusivity. These forward-looking statements are based on managements current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our need for additional funding, which may not be available and which may require us to restrict our operations or require us to relinquish rights to our technologies or Biclonics Triclonics and multispecific antibody candidates; potential delays in regulatory approval, which would impact our ability to commercialize our product candidates and affect our ability to generate revenue; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; the unpredictable nature of our early stage development efforts for marketable drugs; potential delays in enrollment of patients, which could affect the receipt of necessary regulatory approvals; our reliance on third parties to conduct our clinical trials and the potential for those third parties to not perform satisfactorily; impacts of the COVID-19 pandemic; we may not identify suitable Biclonics or bispecific antibody candidates under our collaborations or our collaborators may fail to perform adequately under our collaborations; our reliance on third parties to manufacture our product candidates, which may delay, prevent or impair our development and commercialization efforts; protection of our proprietary technology; our patents may be found invalid, unenforceable, circumvented by competitors and our patent applications may be found not to comply with the rules and regulations of patentability; we may fail to prevail in potential lawsuits for infringement of third-party intellectual property; and our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks.

These and other important factors discussed under the caption Risk Factors in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020 filed with the Securities and Exchange Commission, or SEC, on May 11, 2020, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent managements estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except as required under applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Follow this link:

Merus announces FDA Orphan Drug Designation of Zenocutuzumab for the Treatment of Pancreatic Cancer - BioSpace

It’s time to to start a public conversation about genomics – World Economic Forum

Genomics. Genomic medicine. Personalised medicine. These are very much the buzzwords of our time when it comes to healthcare. But on hearing them for the first time, what do these terms actually mean to people? One research participant who had never heard of the term genomics before, broke the word down phonetically and suggested: "Is genomics something to do with genes and economics?"

It's not an unreasonable question, and it's helpful to be reminded periodically that as a biotechnology community we need to bring everyone up to speed with what we are actually talking about.

Genomics is emerging as one of the main sources of data across many disciplines of medicine and healthcare, so there has never been a more important time to spark public interest in what it can do for people and how they might benefit (and contribute). But how do we start these conversations when often the science, as well as the surrounding language, can seem alien and impenetrable?

It is likely that some of us have already had form of genomic test already, and even if we havent personally, someone we are biologically related to may have done. This may be as part of a routine or in-depth health check, for research purposes or even as part of an online ancestry test.

The first time we come in contact with genomic technology may be an overwhelming or even confusing experience, revealing much more information than we may have anticipated. For others, the situation may be less intense or even recreational, meaning less care will be given about the science that exists behind those tests or consideration of the implications.

Whatever the experience for the individual, it is crucial we reach people with the right information to both dispel the myths around genomics, and make it meaningful. For many, results from genetic tests will end up being a wider conversation, where individuals will be expected to consider what the test means, and its future implications for other relatives.

This means work is needed to find a language that is both memorable and resonates with everyone. But how is this achieved? How can we make genomics and genomic testing seem much less daunting to talk about? What sort of framings narratives, metaphors, mantras and memes can we use to socialise an otherwise dense topic that even healthcare professionals find difficult to navigate?

The only way to achieve a model that works for both professionals and members of the public is to open up dialogue to all groups of people to create a new shared understanding, and an accompanying language that provides clear guidelines around the tools and narratives to be used to achieve best practice. There needs to be a balance of investment where increasing genomic literacy through education (valuable though it is) is only one part of the package. Often what is missed is investment in how to engage and reach currently disconnected members of the public who have never given any thought to the subject. Why is this important? Because as genomic medicine goes mainstream, they may be a patient in waiting or related to someone who is. This means that the relevance of genomics has moved beyond the individual to the family, and then on to broader society.

Healthcare professionals need a clear understanding about how to talk to patients. Recognising that patients do not need to understand the technical concepts to make sense of the testing process, or to make informed choices for themselves and their family, is a first step in creating a mutual respect between these stakeholders. Patients need to feel more confident and familiar with what genomics means for them, and more at ease about discussing it, just as we would for common illnesses.

Its time for us collectively to turn conversations about the impact of genomics into something sociable, easy to navigate and familiar. Just as we have started to embrace discussions on the impact of vaccines and climate change, so too is this necessary for genomics as without it, the impact of genetics will be misinterpreted. Cross-disciplinary expertise is needed for this drawing together input from both the arts and sciences but also from storytellers from the advertising and film industries, and utilising evidence-based engagement and narrative techniques. This evidence must not be one-sided, however, and should incorporate different experiential and social understandings held by different members of society.

The application of precision medicine to save and improve lives relies on good-quality, easily-accessible data on everything from our DNA to lifestyle and environmental factors. The opposite to a one-size-fits-all healthcare system, it has vast, untapped potential to transform the treatment and prediction of rare diseasesand disease in general.

But there is no global governance framework for such data and no common data portal. This is a problem that contributes to the premature deaths of hundreds of millions of rare-disease patients worldwide.

The World Economic Forums Breaking Barriers to Health Data Governance initiative is focused on creating, testing and growing a framework to support effective and responsible access across borders to sensitive health data for the treatment and diagnosis of rare diseases.

The data will be shared via a federated data system: a decentralized approach that allows different institutions to access each others data without that data ever leaving the organization it originated from. This is done via an application programming interface and strikes a balance between simply pooling data (posing security concerns) and limiting access completely.

The project is a collaboration between entities in the UK (Genomics England), Australia (Australian Genomics Health Alliance), Canada (Genomics4RD), and the US (Intermountain Healthcare).

Constructing a global PR campaign takes commitment to messaging, resources and creativity; it also needs collaboration across academia, industry and medicine, with no discipline taking dominance. It also needs to tap into the seldom-heard public voices from people who have had no interaction with this technology yet. It needs to seek out the views of indigenous peoples and representative members of the public, but also those who are fearful and afraid of the technology. Without this collaboration the conversations about genomics will remain disconnected, patchy and without a consistent beneficiary.

This is about all of us not for profit, but for humankind.

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

Written by

Anna Middleton, Professor and Head, Society and Ethics Research Group, Wellcome Genome Campus (Sanger Institute), University of Cambridge

Mavis Machirori, Research Associate, Policy, Ethics and Life Sciences, Newcastle University

Jenniffer Mabuka-Maroa, Consultant, The African Academy of Sciences

Tiffany Boughtwood, Manager, Australian Genomics Health Alliance

The views expressed in this article are those of the author alone and not the World Economic Forum.

Read the original here:

It's time to to start a public conversation about genomics - World Economic Forum

Job guarantee program could bolster economy more than …

While an all-party committee on poverty is reviewing what a basic income guarantee could look like on P.E.I., a suggestion by a Charlottetown social justice group is going one step further with a job guarantee program.

A member of the MacKillop Centre for Social Justice pitchedmembers of P.E.I.'s special committee on poverty on the idea that a job guarantee program would do more than a basic income guarantee to combat the root causes of poverty.

Pavlina Tcherneva is an associate professor of economics at Bard College in New York, who recently published a book titled, The Case for a Job Guarantee.

She says a job guarantee program is essentially an employment safety net a federal employment program administered locally that provides basic job opportunities, with wages and benefits, to those seeking a job that would be more beneficial than basic income.

"In my view, the job guarantee is better, but it certainly coexists with some basic income for people who cannot work for one reason or another but income alone doesn't create the job opportunities that are already missing," she said.

"We really need a transitional program, we need some sort of guarantee that folks that are searching for work can find it. And while basic income may be temporary assistance, folks who receive basic income report that they still need work, they are looking for work and they just cannot find it. So the job guarantee is that mechanism."

People who are out of work, for whatever reason, have a "terrible time" finding employment, Tcherneva said and have a harder time finding work than someone already employed.

"In fact, firms do not like to hire the unemployed, and then they slip into long-term unemployment, and they suffer enormous social and economic costs. So by comparison, the job guarantee will provide first employment opportunity, also the on-the-job training, as well as all of the other support services that unemployment offices provide," she said.

"By comparison with being faced by mass unemployment, having a job is actually really better from the point of view of the employer, but also the program itself will help with placement."

A federally-funded job program also serves to stabilize the economy, Tcherneva argued, ensuring people are able to continue to earn money and, therefore, spend money.

"As we are acutely aware, the economy goes through these cycles, ups and downs, and usually the collateral damage are people they lose their jobs," she said.

"It's that very expenditure that will provide the stimulus to the economy to kick-start private sector activity and employment. As that recovers, then people transition back into private sector jobs, and the public role shrinks, so it is an automatic stabilizer."

Tcherneva said there is often opposition to a job guarantee program, which she believes stems from an ideological bias, but some of the scrutiny that kind of proposal would face may be minimized, given the economic realities created by the COVID-19 pandemic.

"I think also there is this tacit assumption that somehow unemployment is unavoidable and that perhaps unemployment is even necessary to stabilize the economy I think that we really need to question these very deeply," she said.

"We have found occasions in our historical past where we know the government can guarantee employment. Unfortunately, that has happened during wartime but we certainly can do this for civilian purposes. I think it's just the shift of perspective and just realizing that the costs are there and we just can spend our resources in much more fruitful ways."

Meanwhile, P.E.I.'sspecial committee on poverty has asked for a five-month extension until November to decide whether to recommend a basic income guarantee for the province.

Read more:

Job guarantee program could bolster economy more than ...

BTS V, THE LIVING ANIME, GOES VIRAL AGAIN AS MUSE TO FANS WHO RE-IMAGINED THEIR FAVORITE GHIBLI CHARACTERS – allkpop

Anyone who grew up watching animated films can relate when Studio Ghibli is brought up to the conversation. Who can ever forget Howl's Moving Castle? Spirited Away? Princess Mononoke? The Cat Returns?These are only some of the masterpieces produced by one of the criticallyacclaimed studios in the world, which is home to some of the most revered and beloved animated works to have ever graced the screen.

Check out ther site:

http://www.ghibli.jp/

Studio Ghibli's animated works have their distinct visual characteristicsand drawing style,spearheaded by the founder Hayao Miyazaki, who is famous for mostly hand-drawing his animations. This, however, didn't hinder the spirits of BTS fans, who recently displayed their talents in drawing their favorite subject, BTS V, whom they call the LIVING ANIME, by drawing him as their favorite Studio Ghibli characters which recently went viral on Twitter.

Fans can't get enough of the likeness of the characters' drawings to BTS V himself, shown by the intricate details put into the fan arts. This is not the first time, however, that fans have pointed out BTS V's similarity to anime characters, andnot limited to Ghibli alone. Fans have realizedhe resembled a real-life anime and manga characterhighlighting his structured and proportioned face, to his shojo-like expressions, and sometimes his "tsundere"( anime term that depicts a character that's somewhat cold in the beginning but later manifests a warm, sincere,friendlier side over time)aesthetics.

Even the official Twitter account of Anime on Comic Book Com posted that V is the best Muzan incarnateas agreed byDemon Slayer fans.

Notably, this was also highlighted by variousoverseas and Koreanmedia when BTS V performed Singularity in the last leg of their Love Yourself tour,dressed in black feathers with netizens and fanscalling him different names likeBlack Swan, Howl, Evil Prince, Hades for his beauty & charisma on stage. NME, a famousBritish music journalism website wrote rave reviews as "Vhas the entire stadium in the palm of his hand in Singularity, each move as he acts as if hes just woken up in bed wearing a raven-feathered cloak so precise and deliberate, each stare to the camera smouldering and intense" while KBS, one of the major broadcasting networks in Korea, called BTS V's Singularity stageas the highlight of the tourwhichhas taken away the hearts of many viewers.

The global star is not only known for his anime-like and mysterious, princely appearance.V continues to create records inglobal music charts as the First and Only Artist in History who recently dominatedthe iTunes top song charts in 109 countries with his self-produced and composed unpromoted track "Sweet Night" . .

Original post:

BTS V, THE LIVING ANIME, GOES VIRAL AGAIN AS MUSE TO FANS WHO RE-IMAGINED THEIR FAVORITE GHIBLI CHARACTERS - allkpop

Pepe the Frog – Dictionary.com

Artist Matt Furie created Pepe the Frog as an easygoing, bro-like character in his 2005 comic series, The Boys Club. In one comic, Pepe urinates with his pants down at his ankles. Sporting a relieved grin, Pepe says, Feels good man.

Pepes creator told The Daily Dot in April 2015 that the name Pepe (though pronounced differently) evokes pee-pee, in keeping with the literal bathroom humor the original character is known for.

According to Know Your Meme, users began creating their own Pepe images in 2008 in forums on the imageboard site 4chan. These Pepes, riffing on the frogs signature smile, spread online as a humorous reaction, much as people post GIFs to illustrate how they feel about something. One common variant shows a smirking Pepe, often called Smug Pepe, his thumb tucked knowingly under his chin. Additionally, the variants Sad Pepe and Angry Pepe are also common.

By 201415, Pepe had gone full mainstream, with singers Katy Perry and Nicki Minaj notably posting Pepe memes on Twitter. But as The Daily Beast reported in May 2016, some white supremacists were disappointed by Pepes widespread popularity. And so, as a dark and shocking joke, they fashioned Pepes with various anti-Semitic and other racist imagery in efforts to make Pepes widespread use less appealing to those outside their circle. One depicts a caricatured Jewish Pepe smiling at burning Twin Towers on September 11. Another swaps out Pepes Feels good man for Kill all Jews.

Starting around 2015, alt-right supporters of Donald Trump embraced the bigoted Pepe memes, spreading suited-up and blonde-coiffed versions of the frog after the likeness of their candidate. While apparently unaware of Pepes symbolism, Donald Trump retweeted a Trump Pepe in October 2015, as did Donald Trump Jr. following Hillary Clintons basket of deplorables comment in September 2016. Many alt-right social media users have even deployed the frog emoji in their online monikers to represent Pepe and their political affiliations. Pepe has also inspired a hand gesture, resembling the OK sign, that Mediaite claims a ten-year-old flashed on a tour of the White House in March 2017.

This unassuming cartoon frog became so established as a racist symbol that the Anti-Defamation League (ADL) labeled Pepe the Frog as a hate symbol in September 2016. Around this time, the Clinton campaign released their own explainer on Pepe, commenting that the cartoon frog is more sinister than you might realize. Another one of Pepes political iterations is as Pepe Le Pen, which depicts French far-right nationalist politician Marie Le Pen as the frog.

Read the original here:

Pepe the Frog - Dictionary.com

How ‘Pepe the Frog’ went from harmless to hate symbol …

Denizens of the darker corners of the Internetturned an innocent frog comic into a hate symbol of the "deplorable" alt-right.

"Pepe the Frog" first appeared in 2005 in the comic "Boy's Life" by artist and illustrator Matt Furie. The comics depictPepe and his anthropomorphized animal friends behaving like stereotypical post-college bros: playing video games, eating pizza, smoking potand being harmlessly gross.

In 2008, fans of the comic began uploading Furie's work online. In one comic, Pepe responds to a question about his bathroom habits with, "Feels good, man."

That reaction image and catchphrase took on a life of its own on the Internet, meriting a Know Your Meme entry by 2009. Alternate iterations of Pepe, including sad, smugand angry Pepes, followed. Pepe memes are ubiquitous across 4chan, Reddit, Imgur, Tumblr, and other social media and image-sharing sites.

It all seemed in good fun, but in late September, Pepe's green visage was designateda hate symbol by the Anti-Defamation League.

The ADL's online hate symbol database is designed to help law enforcement, educators, and members of the general public identify potentially hateful images, explained Oren Segal, the director of the organization's Center on Extremism. He said that in recent years, hate symbols have proliferated online. Now, with things like Pepe the frog, anti-Semitic images are originating and circulating almost primarily on social media.

In some instances, Pepe wears a Hitler mustache, and his signature message is replaced with "Kill Jews Man." In others, Pepe poses in front of a burning World Trade Center, dressed like an Orthodox Jewish person with a yarmulke and payot. He's also been spotted wearing a Nazi soldier's uniform and in a KKK hood and robe.

In May, the Daily Beast spoke to a white supremacist who said there had been a concerted effort on the site 4chan to "reclaim Pepe" from normal people in late 2015. Pepe had gone mainstream: He's been tweeted by Katy Perry, who said she has a "Pepe file" on her computer, and has made multiple appearances on Nicki Minaj's Instagram. So the supremacist groupremixed him with Nazi propaganda for a laugh.

It originated on /rk9/, the 4chan message board associated with some of the least savory elements of the Internet. Last fall, people on that board purposefully framed two innocent individuals for the Umpqua Community College shooting. It's allegedly where Isla Vista shooter Elliot Rodger announced his shooting before it took place in a post with aPepe meme.

Nazi Pepe made its way to Twitter, where people who regularly tweeted messages supporting white nationalism and anti-immigrant views quickly absorbed it into their Internet repertoire. People who identify with those movementsadd the frog emoji to their Twitter name.

In August, Hillary Clinton gave her now-infamous speech denouncing some of Donald Trump's supporters, particularly the segment known as the alt-right, as a "basket of deplorables."

A couple weeks later, Trump's son Donald Trump Jr. posted a photo on Instagram that depicted him and other supporters as "The Deplorables" -- a play on the poster from the movie "The Expendables." In the lineup? Pepe.

Two weeks after that, the ADL made its official designation. Segal, the representative for the organization, said that while the ADL was researching harassment of journalists on Twitter -- particularly the use of the triple-parenthetical (((echo))) around names to designate Jewish people -- they began to notice Pepe's face coming up more frequently.

He said people on his staff were aware of Pepe's original, inoffensive incarnation, but it was clear that the frog had become associated with anti-Semitic opinions online.

"When we felt that [Pepe]was reaching that point of the hateful version becoming more widespread, that's a criteria for adding it to our hate symbols database," he explained.

Hopefully, he says, the Pepe meme will be able to move past this dark point in its history and go back to just being fun. If enough people share positive -- or at least non-hateful -- Pepe memes, to the point where few people encounter Nazi Pepe online, it wouldn't be a hate symbol anymore.

"The hate symbol database isn't the final stop for this meme," he said.

That came as a big relief to Furie, the artist who created Pepe. He has been understandably devastated by the turn his creation has taken.

"To have it evolve into what it is today, it's a nightmare," Furie said. "It's kind of my worst nightmare ... to be tangled in forever with a symbol of hate."

I would love to help the ADL and do my part by flooding the Internet with positive Pepe memes,he added.

He's not evena particularly political guy. Prior to the ADL's hate symbol announcement, he had never heard of the alt-right or the nascent white supremacist movement that's sprung up around Trump. Though he'd heard of Pepe being used as a meme as far back as 2008, he never made the memes himself. He says he plans to vote for Hillary Clinton.

"I'm a lifelong artist," said Furie, who lives in Los AngelesKoreatown neighborhood. "Hate and racism couldn't be further from something on my radar. I try to focus on positivity and nature and animals."

Furie stopped drawing Pepe about sixyears ago, though he did revive him recently for a very special drawing on his Tumblr. It depicts the frog wearing a "Make Pepe Great Again" hat, urinating on a green-faced Trump.

Reclaiming your own work from anti-Semites: Feels good, man.

@jessica_roy

jessica.roy@latimes.com

ALSO

Live updates from the campaign trail

Trump is encouraging and amplifying the message of a 'radical fringe' of conservatives, Clinton says

Continued here:

How 'Pepe the Frog' went from harmless to hate symbol ...

States need greater fiscal space to meet their expenditure obligations: NK Singh – Economic Times

Pushing for a relaxation in fiscal norms governing the finances of the states, NK Singh, chairman of the 15th Finance Commission, said states needed greater fiscal space to meet their expenditure obligations.

Clearly, the finances of the states are under stress, there are issues of fiscal pressure. This is a time, when I believe, some of the basic tenets of the fiscal norms need to be suitably relaxed. This is a time when states need greater freedom to be able to meet their initial obligations, on account of this pandemic, Singh said on Wednesday.

Singh was delivering a lecture on the impact of the pandemic on fiscal architecture and fiscal federalism in the near future, to students of the Indian Institute of Management, Bangalore.

According to Singh, the opaqueness and clutter in the demarcation of powers of the central and state governments under the Constitution and other Acts posed a hindrance to Indias pandemic response.

In the short term, Singh called for greater harmony between the Disaster Management Act, 2005, and the Epidemic Diseases Act, 1897, both of which have been invoked in the process of responding to the pandemic.

In the short term, there are issues of dealing with the clutter of the Disaster Management Act and the Epidemic Act. They need to have greater harmony, he said.

The older legislation demarcates powers of the Centre and state governments in their response to an epidemic. It grants states powers over laws governing people within its jurisdiction while the Centre is empowered to dictate terms on ports of entry.

A similar confusion exists due to the demarcation of powers under the seventh schedule of the Constitution, according to Singh. The schedule deals with subjects under the purview of the Central and state governments and those that are governed by both.

Until the seventh schedule is cleaned up, fiscal architecture, as we go forward, will remain clumsy and ill-designed to suit the contemporary needs, Singh said, stating that circumstances are very different now compared to when the Constitution was drawn up.

Continued here:

States need greater fiscal space to meet their expenditure obligations: NK Singh - Economic Times

Canadians’ right to information should not be compromised: commissioner – The Tri-City News

While the COVID-19 pandemic has slowed Ottawas handling access to information requests, the countrys law enforcement agencies and defence department are often unable to meet legislated response requirements, government documents show.

Indeed, in some cases, compliance with legal requirements on freedom of information (FOI) is declining.

Its a situation contributing to a lack of information from the federal government that Canadians need to participle fully in a democratic society, said Mount Royal University journalism Prof. Sean Holman.

He said governments are more in the business of denying information requests than they are about being open.

Were actually talking about the censorship of material prior to release, he said.

And, its something Information Commissioner of Canada Carline Maynard identified in an April letter to federal Treasury Board president Jean-Yves Duclos.

Given the scale of the pandemic response, institutions can anticipate a surge of access requests related to the governments handling of the response to COVID-19, Maynard wrote. Without outstanding leadership and proper planning, we can foresee that the new backlog generated during the current crisis will become another systemic burden, further impeding a system that is already facing major challenges. Simply put, this cannot become the new normal.

Glacier Media examined the most recent freedom of information reports from the RCMP, the Canadian Security Intelligence Service (CSIS), Canada Border Services Agency (CBSA) and the Coast Guard.

The reports detail how responsive each of the agencies is to information requests under the federal Access to Information Act (ATIP).

Department of National Defence (DND)

In a report to Parliament July 22, Maynard examined DND handling of requests. In her recommendations, she said other government institutions should take note. Canadians have a quasi-constitutional right to access government information is not compromised, she said.

Among recommendations were better record keeping about searches, greater use of technology instead of moving paper, increased communication with requesters, mandatory training in request handling, dedicated response officers in high-volume situations and knowledge of legislation to avoid obstruction problems.

In a February 28 response to her findings, Minister of National Defence and Vancouver South MP Harjit Sajjan wrote, access to information is a critical right, and the department is committed to open government initiatives and is continually improving its access to information program.

RCMP

In 2017-18, the RCMP received 10,199 requests. Some 3,289were held over from the prior year. For the year, 6,051 requests completed and 7,437carried forward.

For 2016-17,the force received 9,965 ATIP requests with1,454 ATIP requests outstanding from the prior fiscal year; 8,130 ATIP requests completed; and 3,289 ATIP requests carried forward to the next fiscal year

In 2015-16, the RCMP received 8,469 requests. There were1,200 requests outstanding from the previous year. Some 8,122 requests were completed and 1,277 carried forward to the next fiscal year.

There was no explanation for difference between the 1,277 carried forward in 2015-2016 and the 1,454 outstanding from the same year.

An audit found compliance with the law for responding to requests continue to decline, 78.2% for 2015-16,65.4% for 2016-17,and 33.5% for 2017-2018.

The number of complaints is also increasing. That number sat at 140 in 2014-2015, dropping to 120 the next year. It rose to 160 in 2016-2017 and leapt to 232 for 2017-2018.

In 2017, the force asked for 61 new employees to handle the caseload. It received 12.

The audit, released in March, said initiatives have been launched to improve effectiveness and efficiency but said implementation of initiatives appears to be reactive with limited documented analysis to support managements decision to pursue proposed initiatives. It said the RCMP would benefit from the development of a formal plan to manage the implementation of process improvement initiatives and measure their success.

The 35% response time for 2017-2018 concerns Holman.

Its not just how the access offices are being run and the RCMP are being run that is getting in the way of disclosure, he said. Its about the RCMP attitude toward disclosure.

That, he said, should be a matter of public concern.

Canada Border Services

Canada Border Services said it has closed more files than it received in 2018-19. Of the 1,362 requests carried over to fiscal year 20192020, 1,220 were on time and 142 were late, the services January report to Parliament said.

The service said 94.3% of 2019-2020 requests were completed within the legislated timelines, an increase from 86.8% the previous year.

CBSA said it requested 2,237response time extensions in2018-19, up 16% over the previous year, a change is attributed to an increase in requests.

For 20182019, 150 complaints were filed against CBSA, up 35.4% over 2017-18.

CSIS

The intelligence agencys February report to Parliament said it is seeing request increases year over year.

CSIS received 1,146 requests in 2018-2019 up from 851 in 2017-18 and 491 in 2016-17. The bulk come from the public followed by businesses and then media.

Although faced with a significant increase in volume from the previous fiscal year, the service closed 1,181 requests and maintained a high on-time compliance rate of 98.1 % with a 1.9 % deemed refusal rate. As of April 1, 2019, 10 requests received during the 2018-2019 fiscal year were in a deemed refusal situation.

CSIS noted a significant backlog of consultations involving Library and Archives Canada accumulated during the year due to the immense number of records involving dated RCMP and CSIS security intelligence files as well as the complexity and sensitivity of the information contained therein. The service is working on identifying solutions to address this growing challenge.

CSIS registered 25 new complaints in the period and closed 61. Some 83 remain active.

Holman said the real problem with the ATIP process generally is that it allows for exemptions and exclusions.

He said Canada should be looking at general releases of broad categories of information.

Thats something a group Holman is involved in called for in May, saying Canadians deserve greater information transparency and protection for whistleblowers.

jhainsworth@glaciermedia.ca

@Jhainswo

See the rest here:

Canadians' right to information should not be compromised: commissioner - The Tri-City News

Reopening the doors of perception: The psychedelics renaissance in Canada – Lexology

While cannabis takes a breather from the capital markets roller coaster ride that has characterized that sector lately, psychedelics are in the news lately and all the rage in the capital markets. Junior pharmaceutical companies, specialized clinics and Caribbean retreats are common water-cooler topics of conversation these days among capital markets investors and observers alike. To be sure, momentum is building and public perception is changing in Canada and in some parts of the United States toward reducing barriers to access for psychedelics. Low enforcement priorities in Denver, Oakland and Santa Cruz, as well as Oregons proposed laws to regulate cultivation, manufacture and sale of psilocybin products for medical purposes, broadens the discussion. Todays momentum has been a long time coming particularly as a viable new option for mental health treatment.

Psychedelics, entheogens, entactogens and dissociative anesthetics are a broad group of substances that are intensely psychoactive, with effects including visual and other illusions, mystical-type experiences, synesthesia, intensified emotional states and other disorienting effects. Duration of these effects may range from 15 minutes or less to more than 24 hours. The terms for these compounds and the plants or fungi they are sourced from vary depending on the perspective and context. For simplicity, we use the term familiar to most psychedelics as a blanket term for psychedelics, entheogens, entactogens and dissociative anesthetics.

Prohibition, regulation and sale

Psychedelics are not illegal. That said, many psychedelics are scheduled in the Controlled Drugs and Substances Act (the CDSA), making them controlled substances and unless otherwise authorized, possession and manufacture of any controlled substance is prohibited. Most psychedelics that are controlled substances are within a certain class of controlled substances called restricted drugs. Investigators for clinical trials, preclinical studies and other researchers may possess restricted drugs through exemptions issued under the CDSA. Authorization to manufacture, compound, package and otherwise work with restricted drugs is available through a dealers licence issued under the Food and Drug Regulations (the FDR).

Like any drug substance, a drug product including a psychedelic substance as an active pharmaceutical ingredient (API) is saleable under the FDR once a drug identification number (DIN) is issued by Health Canada for use of the drug product in association with a given therapeutic indication. Clinical evidence establishing safety of a drug product and efficacy for treating a given condition is required for Health Canada to issue a DIN for the drug product. An MDMA drug product is on track to receive a DIN for use in treatment of post-traumatic stress disorder (PTSD) and the equivalent regulatory approval in the United States within the next two to four years. A psilocybin drug product for treatment-resistant depression appears to be close behind.

Psychedelics and mental health

Administration and application of psychedelic drugs diverges from previous approaches to the use of medication for treatment of mental health disorders. This point of divergence changes the economics of cost recovery for clinical trial expenses after being issued a DIN. Drug products traditionally used in treatment of mental health conditions are taken daily and unsupervised at dosage ranges intended to suppress symptoms of mental illness and to minimize overtly psychoactive effects. In contrast, in clinical trials MDMA and psilocybin are typically administered a small number of times at strongly psychoactive flood doses in a supervised therapy setting. Similar approaches will be followed in applications using flood doses of LSD, and for use of MDMA and psilocybin for other therapeutic indications. Clinics that currently administer racemic ketamine off-label for treatment of depression follow a similar model.1

The long duration of the effects resulting from a flood dose of most psychedelics increases the time required from therapists, often in specialized clinic settings designed to maximize the benefits of the psychoactive effects of psychedelics. Compared with previous approaches to management of mental health conditions, psychedelic assisted therapy uses a lower amount of drug substance and involves a greater amount of time spent with therapists. As a result, a much greater portion of the value chain for administration of a psychedelic drug product is captured by therapists relative to the manufacturer of the drug product. Microdosing psychedelics, which is generally defined as taking about five to ten per cent the dosage of a flood dose, presents a potential commercialization pathway for a drug product to be taken regularly and without supervision.

Mental health is a serious problem globally. This problem is likely exacerbated by the current global pandemic. Based on scientific evidence, psychedelics are likely to play a significant role in correcting this problem. Particularly in the last ten years or so, there has been growing attention on psychedelics and their potential therapeutic applications. World-class academic institutions and sophisticated, well-financed public companies are studying the potential benefits of LSD, psilocybin, MDMA, ibogaine and DMT for indications including end of life depression, treatment resistant depression, PTSD, eating disorders, Alzheimers disease, substance use disorder and others. Commercialization efforts are underway and we can expect to see MDMA, psilocybin and potentially other psychedelics used as APIs in drug products holding a DIN.

Psychedelics are not cannabis

While it is natural to draw a comparison to cannabis, psychedelics are not the next cannabis. Cannabis products are a commodity-based and highly regulated category of consumer packaged goods (CPG). Cannabis has a well-defined adult use market that was built on a multi-participant commercial medical cannabis industry. Cannabis is also commonly used on a daily basis. Robust consumer demand for cannabis products supports an industry including cultivation, processing, retail sale and all the picks and shovels needed to maintain consumer access to cannabis products.

In contrast to cannabis, there is no psychedelics industry at least not today. Rather, psychedelics are a disruptor for health care delivery and pharmaceuticals. Cannabis is a single heterogeneous commodity in high demand for manufacture of CPGs. In contrast, psychedelics are a diverse group of chemicals that vary widely in their effects.2 Also contrasting with a commodity-based CPG industry, psychedelics for use in a therapeutic context are typically used sparingly and can currently be commercialized only as drug products regulated under the FDR.

There is plenty of noise circulating around psychedelics. While drug products holding a DIN and including a psychedelic substance API are likely to disrupt how therapy is delivered, there is no medical access program in Canada similar to the Marihuana for Medical Purposes Regulations for any psychedelics and there may never be. We believe that the market, and the strengths that distinguish the leaders, will be very different for psychedelics compared with cannabis.

The rest is here:

Reopening the doors of perception: The psychedelics renaissance in Canada - Lexology

GreenStar Biosciences Completes Acquisition of 100 Percent of Eleusian Biosciences Corp. and Appoints Jonathan Gilbert to Board of Directors and…

Strategic acquisition by GreenStar adds innovative company focused on the development of effective therapeutics using psychedelic medicine

GreenStar Biosciences Corp. (CSE:GSTR) (OTC Pink:GTSIF) (GreenStar or the Company) is pleased to announce, further to its press release dated July 21, 2020, that it has completed the acquisition of 100% of Toronto, Ontario-based Eleusian Biosciences Corp. (Eleusian) (the Transaction) through the issuance of common shares of GreenStar. In addition, the Company is pleased to announce the appointment of Mr. Jonathan Gilbert to the Companys board of directors and Mr. Maghsoud Dariani as its Chief Science Officer.

Highlights:

With the acquisition of Eleusian and appointments of Mr. Gilbert and Mr. Dariani, GreenStar believes it represents a new standard for excellence within the psychedelic medicine industry. GreenStar will now have a very strong business development team complemented by experts to identify new market growth opportunities.

Jonathan Gilbert, is an accomplished business executive with a successful exit in the psychedelics sector. Previously, he was the CEO of Scythian Biosciences, Inc., a publicly traded research and development company focusing on the prevention and treatment of concussions and traumatic brain injury using a proprietary cannabinoid combination. Mr. Gilbert is also experienced in strategic investments and partnerships related to the cultivation, distribution and retail sale of legal cannabis.

I am very pleased to join the board of directors of GreenStar. This is an exciting step as GreenStar and Eleusian come together to realize our common objective of building a premier therapeutic wellness business focused on development of effective therapeutics using psychedelic medicine, said Jonathan Gilbert. I look forward to working with the board and management team to further expand new opportunities and development initiatives.

We are extremely pleased to complete the acquisition of Eleusian and add such well-regarded industry executives as Jonathan and Maghsoud to our board of directors and senior management team. Eleusians focus on developing proprietary technologies in addition to development work involving psilocybin, NAC and MDMA for mTBI, PTSD and brain injuries is extremely exciting, said Thomas Baird, GreenStar CEO.

The Transaction was completed pursuant to exemptions from the prospectus and registration requirements under applicable securities laws. None of the GreenStar Shares issued to Eleusian shareholders in connection with the Transaction were registered under the United States Securities Act of 1933, as amended, and none may be offered or sold in the United States absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any GreenStar Shares, nor shall there be any distribution of GreenStar Shares in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About GreenStar

GreenStar is a growth-oriented technology and services company that provides real estate, financial, management, IP and branding support to businesses. The Company operates a growing portfolio of tenant partner companies focused on transformational medicine and applies refined strategies to help partner companies reach their full potential. Based in Vancouver, BC, GreenStar intends to facilitate growth through acquisitions and development of additional assets, products and technologies by leveraging its capital markets, branding and operational expertise.

About Eleusian

Eleusian Biosciences Corp., a Toronto based company, is focused on development of therapeutics for multiple pathological psychological diseases based on psilocybin plus N-Acetylcysteine (NAC) compounds. Eleusian is collaborating with a multidisciplinary team of scientists and physicians at the Miller School of Medicine at the University of Miami to develop effective therapeutics for the treatment of mTBI (mild traumatic brain injury/concussion) with PTSD or PTSD alone based on Psilocybin (the active ingredient of psychedelic mushrooms) and NAC. NAC has been shown to have efficacy in treating mTBI, particularly in reducing neuronal losses and also reducing impaired cognitive and neurological symptoms after injury to head. For more information, visit the companys website atwww.eleusian.bio.

For further information please contact:

GreenStar Biosciences Corp.Thomas Baird, CEOinfo@greenstarbiosciences.comTel: (604) 834-9499

THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACYOR ADEQUACY OF THIS RELEASE.

Disclaimer for Forward Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as will, may, should, anticipate, expects and similar expressions. All statements other than statements of historical fact, included in this release, including statements regarding the future plans and objectives of the Company, the acquisition of Eleusian, the Companys expansion initiatives and pursuit of M&A activity are forward looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Companys expectations are risks detailed from time to time in the filings made by the Company with securities regulations. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment; and that the current Board and management may not be able to attain the Companys corporate goals and objectives. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

Source

More:

GreenStar Biosciences Completes Acquisition of 100 Percent of Eleusian Biosciences Corp. and Appoints Jonathan Gilbert to Board of Directors and...

Capstone to Expand Leaching at Pinto Valley; 300 to 350 MIbs of Low-Cost, Copper Cathode Production Potential – Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)--Capstone Mining Corp. (Capstone or the Company) (TSX:CS) announces that its Pinto Valley mine has successfully demonstrated positive economics from enhanced dump leach performance by partnering with Jetti Resources, LLC (Jetti) to apply their novel patented catalytic technology at Pinto Valleys existing dump leach operation.

HIGHLIGHTS

During the first year of Capstones partnership with Jetti, cathode production per area irrigated has doubled (see Figure 3). A plan to increase activity is being implemented with the goal of generating strong cash flow from Pinto Valleys underutilized 25 million pound per year solvent extraction and electrowinning (SX-EW) plant, which is currently operating at only 20% of capacity. The plan is to increase cathode production to 300-350 million pounds from residual and high-grade waste over the next two decades (see Figure 1), creating 30 new jobs at Pinto Valley.

Figure 1: Low Cost Recovery of Copper from Residual and High-Grade Waste

Darren Pylot, Capstones President and CEO said, The mining industry has long been pursuing a viable technology to leach low-grade chalcopyrite ores. The results after year one of our partnership with Jetti Resources are exciting because it means we can generate high margin from material that would have been waste. This project represents an opportunity to position Pinto Valley more competitively, which will create and sustain jobs, and economic benefits in a socially and environmentally responsible manner.

The engagement of Jetti and utilization of their proprietary technology was an extension of Pinto Valleys existing PV3 Optimization Study, which is focused on several low capex, high impact projects aimed at having a material increase to the net present value of the operation. The PV3 Optimization Study is scheduled for release in Q4 2020.

JETTI NOVEL CATALYST TECHNOLOGY

Jettis patented technology makes it possible to extract copper from low-grade primary sulfides, such as chalcopyrite, the worlds most abundant copper mineral ore. Jetti has developed and commercially deployed a catalytic technology that allows for the efficient and effective heap and stockpile leach extraction of copper trapped in these challenging mineral ores. Jettis catalysts enable the disruption of the sulfur metal bond of the mineral, allowing copper extraction to take place unimpeded. As a result, Jetti is now increasing profitability at operations and extending project life, while also converting uneconomic waste rock into valuable assets.

Figure 2: Surface of Chalcopyrite Leach Residue With and Without Jetti Catalyst

Mike Outwin, Jetti Resources Co-Founder and CEO said, Pinto Valley was a perfect candidate to pioneer our breakthrough technology given the abundance of copper resources available for leaching and the underutilized plant and infrastructure in place. Our technology has integrated seamlessly with the existing infrastructure on site, and we have doubled the production of copper cathode per area irrigated within one year of our partnership. We are excited to partner with Capstone to realize more economic value from their vast copper resource in Arizona and possibly other projects in the Americas.

Figure 3: Copper Cathode Production Per Area Irrigated Doubled

In 2019, Jetti started deploying its novel catalytic technology at Pinto Valley's leach operation and, one year later, has now doubled copper cathode production per area irrigated.

PINTO VALLEYS CATHODE PRODUCTION HISTORY

Pinto Valley started producing copper cathode in 1981 from material below the cut-off grade of its mill that had been stockpiled since the early 1970s (see Figure 4). This provided a 12 to 15% boost to total copper production as cathode accounted for an average of 16 million pounds per annum through to the early 2000s. Since then, the production of copper cathode has decreased consistently to under four million pounds per annum due to the impact of reduced leach kinetics as chalcopyrite is subjected to a passivation layer inhibiting further breakdown.

Figure 4: Historical Production at Pinto Valley

NEXT STEPS

As a result of the positive commercial demonstration phase, Pinto Valley intends to significantly expand leaching activity, targeting approximately 280 to 300 million tonnes of historic leach stockpile and 175 to 185 million tonnes of high-grade waste already scheduled for removal over the remaining 19 years of mine life. Potential to increase the mill cut-off grade to bolster copper concentrate production, thereby increasing the tonnage of high-grade waste available for leaching, will be studied during H2 2020. An updated NI 43-101 Technical Report is expected in 2021.

Figure 5: Pinto Valley Dump Leach Area

Figure 6: Aerial Photo of 25 Million Pound Per Year SX-EW Plant

The SX-EW plant is currently only 20% utilized.

Figure 7: High-Grade Waste Area

A total of 11 to 12 million tonnes of high-grade waste has been placed since early 2019 and by the end of 2022, approximately 48 to 52 million tonnes are expected to be under irrigation.

Figure 8: July 2020 LME Grade A Copper Cathode Waiting for Pick-Up

ABOUT CAPSTONE MINING CORP.

Capstone Mining Corp. is a Canadian base metals mining company, focused on copper. Our two producing mines are the Pinto Valley copper mine located in Arizona, US and the Cozamin copper-silver mine in Zacatecas State, Mexico. In addition, Capstone has a large scale, fully-permitted, 70% owned copper-iron-gold Santo Domingo project in Region III, Chile, in partnership with Korea Resources Corporation, as well as a portfolio of exploration properties. Capstone's strategy is to focus on the optimization of operations and assets in politically stable, mining-friendly regions, centred in the Americas. We are committed to the responsible development of our assets and the environments in which we operate. Our headquarters are in Vancouver, Canada and we are listed on the Toronto Stock Exchange (TSX). Further information is available at http://www.capstonemining.com.

COMPLIANCE WITH NI 43-101

Unless otherwise indicated, Capstone has prepared the technical information in this news release based on information contained in the technical reports and news releases (collectively the Disclosure Documents) available under Capstone Mining Corp.s company profile on SEDAR at http://www.sedar.com. Each Disclosure Document was prepared by or under the supervision of a qualified person (a Qualified Person or QP) as defined in National Instrument 43-101 Standards of Disclosure for Mineral Projects of the Canadian Securities Administrators (NI 43-101). For readers to fully understand the information in this news release, they should read the Technical Reports (available on http://www.sedar.com) in their entirety, including all qualifications, assumptions and exclusions that relate to the information set out in this presentation which qualifies the Technical Information. Readers are advised that mineral resources that are not mineral reserves do not have demonstrated economic viability. The Disclosure Documents are each intended to be read as a whole, and sections should not be read or relied upon out of context. The Technical Information is subject to the assumptions and qualifications contained in the Disclosure Documents. For further details refer to the Companys NI 43-101 Technical Reports for Pinto Valley Mine Life Extension Phase 3 (PV3) Pre-feasibility Study, Miami, Arizona, published Feb 23, 2016, effective Jan 1, 2016.

The Technical Information in this presentation has been prepared in accordance with NI 43-101 and reviewed and approved by Colleen Roche, Capstone Pinto Valleys Manager, Operations Support, a Qualified Person as defined in NI 43-101.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

This news release, and the documents incorporated by reference herein, contains forward-looking information within the meaning of Canadian securities legislation and forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 (collectively, forward-looking statements). These forward-looking statements are made as of the date of this document and Capstone Mining Corp. (Capstone or the Company) does not intend, and does not assume any obligation, to update these forward-looking statements, except as required under applicable securities legislation. Forward-looking statements relate to future events or future performance and reflect our expectations or beliefs regarding future events. Forward-looking statements include, but are not limited to, statements with respect to the continuing success of mineral exploration, Capstones ability to fund future exploration activities, the estimation of mineral resources and mineral reserves, the realization of mineral reserve estimates, the timing and amount of estimated future production, costs of production and capital expenditures, the success of our mining operations, the estimation of increased cathode production, the ability to obtain required permits for the intended expanded leaching activity, the estimation of the expected economics of the expanded leaching activities, the estimations for potential quantities and grade of inferred resources and exploration targets, environmental risks, unanticipated reclamation expenses and title disputes. In certain cases, forward-looking statements can be identified by the use of words such as plans, expects, aiming, approximately, guidance, scheduled, target, estimates, forecasts, extends, convert, potential, intends, anticipates, believes or variations of such words and phrases, or statements that certain actions, events or results may, could, should, would, will, might or will be taken, occur or be achieved or the negative of these terms or comparable terminology. By their very nature, forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include, amongst others, risks related to inherent hazards associated with mining operations and closure of mining projects, the inherent uncertainty of mineral exploration and estimations of exploration targets, potential delays in exploration or interruption of production directly or indirectly related to COVID-19 or governmental action, future prices of copper and other metals, compliance with financial covenants, surety bonding requirements, our ability to raise capital or fund explorations, Capstones ability to acquire properties for growth, counterparty risks associated with sales of our metals, foreign currency exchange rate fluctuations, changes in general economic conditions, risks associated with hedging strategies, accuracy of mineral resource and mineral reserve estimates, operating in foreign jurisdictions with risk of changes to governmental regulation, compliance with governmental regulations, compliance with environmental laws and regulations, reliance on approvals, licences and permits from governmental authorities, impact of climatic conditions on our operations, aboriginal title claims and rights to consultation and accommodation, land reclamation and mine closure obligations, uncertainties and risks related to the potential development of the Cozamin project, increased operating and capital costs, challenges to title to our mineral properties, maintaining ongoing social license to operate, dependence on key management personnel, potential conflicts of interest involving our directors and officers, corruption and bribery, limitations inherent in our insurance coverage, labour relations, increasing energy prices, competition in the mining industry, risks associated with joint venture partners, our ability to integrate new acquisitions into our operations, cybersecurity threats, legal proceedings, and other risks of the mining industry as well as those factors detailed from time to time in the Companys interim and annual financial statements and MD&A of those statements, all of which are filed and available for review under the Companys profile on SEDAR at http://www.sedar.com. Although the Company has attempted to identify important factors that could cause our actual results, performance or achievements to differ materially from those described in our forward-looking statements, there may be other factors that cause our results, performance or achievements not to be as anticipated, estimated or intended. There can be no assurance that our forward-looking statements will prove to be accurate, as our actual results, performance or achievements could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on our forward-looking statements.

See the original post here:

Capstone to Expand Leaching at Pinto Valley; 300 to 350 MIbs of Low-Cost, Copper Cathode Production Potential - Business Wire

NFL and its players head to training camp ready to tackle life in a pandemic – KEYT

Of all the team sports, football and social distancing dont seem to go together. But even in the middle of a deadly pandemic, the NFL is readying to bring a sense of normalcy back to a stressed-out country.

Training camps are preparing to open this week, welcoming back 32 teams, some of them in areas that are Covid-19 hot spots.

There are some officials who think football should skip a season or push it back until the spring. Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, told CNN in June that it would be very hard to see how football is able to be played this fall if NFL and college players were not living in isolation and being tested every day.

Football may not happen this year, he said at the time.

But the league feels confident at this point a full slate of 16 games per team is possible, given the protocols it has agreed on with the players..

I think people are trying to be really thoughtful about this, said Dr. Allen Sills, the NFLs chief medical officer and a neurosurgeon. He sat down exclusively with CNN Chief Medical Correspondent Dr. Sanjay Gupta and gave him a rare look at how the Atlanta Falcons and the NFL are preparing to play in the midst of a pandemic.

I think people do look at risk and risk mitigation in different ways. But I feel like its the right thing to do to try to learn to live with this virus. I really do, Sills told Gupta.

But the NFL may have to consider new measures, given the news from Major League Baseball that members of the Miami Marlins tested positive for the virus. Mondays Marlins home opener and the game between the Yankees and Phillies at Philadelphia where Miami played over the weekend were postponed.

Normally, by this time, NFL teams would have already had several offseason gatherings and scores of players would be days into training camp, vying for one of the potential 55 spots on the roster. More than 250 coaches, staffers and other on-site personnel would be around.

Players would be going to team meetings, working out in the weight room, busting heads on the field and eating together in a cafeteria.

But more than 4 million people in the United States have been infected with the virus and more than 147,000 Americans have died. It is unclear whether people who have recovered have any immunity from the virus. A few therapeutics help those with Covid-19, but potential vaccines are still in various phases of trial.

Sills likened his work in bringing back football to his work with his patients.We know in medicine, we can never eliminate risk, but we do all we can to try to minimize or mitigate those risks, Sills told Gupta.

Testing has been a key component in bringing players back. As players enter camp, they will be tested. Players have to have two negative tests within 72 hours in order to participate in training camp.

Thereafter, the union and the league have agreed to test each player daily for at least the first two weeks of training camp, eventually moving to an every-other-day schedule once a team maintains a 5% positivity rate.

Those tests will be conducted by the company BioReference Laboratories. Sills told Gupta that the company opened up laboratory capabilities that werent being used.

Both the league and union have said they dont want their testing program to take away resources from the public.

In the early days, Sills expects they will discover people who are infected.

Last week, based on players who signed into training camp and did their initial testing, the players union said 59 players had tested positive for the novel coronavirus.

First of all, we fully expect to have positive cases. We would love it if we didnt, Sills told Gupta before the test results were announced. But if you look at the state of the pandemic right now, I think when players all gather together, we can expect a large number of positive cases.

Once a player tests positive, he will go into isolation and get the appropriate treatment, Sills said.

And though the public often sees NFL players as men who are in top physical condition, the union says its data shows up to 70% of players fall into categories the Centers for Disease Control and Prevention considers high risk for Covid-19, such as minorities and people with certain health conditions that include obesity and asthma.

What weve done is track the CDC risk guidelines (and) made decisions on which ones put our players in high risk, explained DeMaurice Smith, executive director of the National Football League Players Association. Players can rely on those risk factors to make decisions about whether theyre going to play or not.

Technology could help the league try to mitigate some risk.

Players will have a proximity tracing device on them while they are participating in team activities, even traveling to road games. The devices can provide precise data as to who the players were near, how close they were and for how long.

The devices will beep or flash when players or staff get too close to each other and could make it much easier to do contact tracing when a player tests positive. The device does not track GPS location it just tracks distance.

The league has also worked with sports apparel company Oakley to design a plastic mouth shield for the players helmets. It is basically an extension of the eye shield some players wear, Sills said. It will have several layers of plastic and a filtering material in hopes of helping to lowering transmission. How effective it is remains to be seen.

According to the NFL, players are strongly encouraged to use the mouth shield. It is currently not mandatory, but is still under discussion between the NFL and the Players Association.

Other changes include the way players typically would congregate.

At the Falcons facility, the dining area has been moved outside under a tent and players will sit solo at tables several feet apart. Weights will be done at a scheduled time with fewer players and barbells will be marked with tape signifying which ones are to be used by a certain group.

Meetings and film-watching sessions will be online instead of in person.

Normally, players would work with a staff of around 200 plus people. But now, only 100 staff will be credentialed to be at the practice facility.

Our motto is fewer and farther, Sills said.

At the training facility, staff will spray down equipment in training rooms and there will be black boxes that use UV light to sanitize cell phones and car keys.

The league and the union have been intense negotiations over the past few weeks about how to get players back on the field. They discussed a number of issues, including testing protocols, who players can interact with and how, and what options players have to opt out, and finally came to an agreement on Friday.

Shortly thereafter, Kansas City Chiefs offensive guard Laurent Duvernay-Tardif chose to opt out of playing this season to focus on his work as an orderly in a long-term care facility in Canada. Hes been working there throughout the pandemic.

Being at the frontline during this offseason has given me a different perspective on this pandemic and the stress it puts on individuals and our healthcare system, he wrote. I cannot allow myself to potentially transmit the virus in our communities simply to play the sport that I love. If I am to take risks, I will do it caring for patients.

The head of the players union told CNN he wants the league to have better communication with the athletes and their families.

We have great protocols. While we have the ability to make inspections, if the league fails to stay into close contact with the players in their families and making those changes as needed, the best protocols in the world will not work, Smith said.

Decisions affect the entire community, not just the league, he said.

Everything that we do is going to have an impact on families at home, and its going to have an impact on first responders, community service and other people in the community, and to believe otherwise is sheer fantasy, he told CNN.

The most recent NFL game was the Super Bowl in early February two days after US officials declared a public health emergency. A month later, the nation took notice as the NBA took players off the court before a scheduled game and the nature of the pandemic became much more real to many people.

Since then, team training facilities have been like ghost towns. Players have worked out with personal trainers while keeping an eye on how states were handling the pandemic

They have the same anxiousness that you would have, right. All the issues that you have about your personal safety they have. And they have them as they enter into this football world, said Rich McKay, president and CEO of the Falcons. So, theyre relying on us. And theyre relying on the union to make sure that all the protocols we do, everything that we can, is that at the highest level.

McKay said they will proceed slowly at first.

We want to crawl, he told Gupta. We dont even want to walk, jog, run. We want to crawl, then we want to walk, then we want to jump. We want to make sure they feel safe, feel comfortable and that were doing everything we can.

McKay believes the NFL can do everything in a safe way, learning from the lessons of the other team sports leagues that have opened before it. But unlike the NBA and MLS, which have all of their teams in one city, NFL players will be in dozens of communities, going home at night.

The system can only be strong if NFL personnel adhere to guidelines.

One of the things that weve recognized with this virtual bubble is everybody in that team ecosystem, as we call it, theyre going to share risk, right players, coaches, staff, if theyre around each other each day, theyre going to share risk, Sills said. They also share responsibility to each other, which means that theyre each making good choices when theyre away from the facility.

The NFL season is scheduled to begin Thursday, September 10.

View post:

NFL and its players head to training camp ready to tackle life in a pandemic - KEYT